S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
Log in
NASDAQ:VKTX

Viking Therapeutics Stock Forecast, Price & News

Top-Rated Stocks  
$6.82
+0.03 (+0.44 %)
(As of 01/22/2021 04:44 PM ET)
Add
Compare
Today's Range
$6.57
Now: $6.82▼
$6.89
50-Day Range
$5.63
MA: $6.29▼
$6.86
52-Week Range
$3.26
Now: $6.82▼
$8.36
Volume966,092 shs
Average Volume1.21 million shs
Market Capitalization$497.53 million
P/E RatioN/A
Dividend YieldN/A
Beta2.02
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Viking Therapeutics logo

MarketRank™

Overall MarketRank™

1.58 out of 5 stars

Medical Sector

327th out of 1,922 stocks

Pharmaceutical Preparations Industry

170th out of 769 stocks

Analyst Opinion: 3.6Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VKTX
Previous Symbol
CUSIPN/A
CIK1607678
Webwww.vikingtherapeutics.com
Phone858-704-4660
Employees17

Debt

Debt-to-Equity RatioN/A
Current Ratio27.08
Quick Ratio27.09

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.83 per share
Price / Book1.78

Profitability

EPS (Most Recent Fiscal Year)($0.36)
Net Income$-25,780,000.00
Net MarginsN/A
Return on Equity-13.57%
Return on Assets-13.14%

Miscellaneous

Outstanding Shares72,952,000
Market Cap$497.53 million
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$6.82
+0.03 (+0.44 %)
(As of 01/22/2021 04:44 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions

How has Viking Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Viking Therapeutics' stock was trading at $5.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VKTX stock has increased by 34.5% and is now trading at $6.82.
View which stocks have been most impacted by COVID-19.

Is Viking Therapeutics a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Viking Therapeutics stock.
View analyst ratings for Viking Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Viking Therapeutics?

Wall Street analysts have given Viking Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Viking Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Viking Therapeutics' CEO?

1,448 employees have rated Viking Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Viking Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Viking Therapeutics' next earnings date?

Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Viking Therapeutics.

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) released its earnings results on Wednesday, October, 28th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.02.
View Viking Therapeutics' earnings history.

What price target have analysts set for VKTX?

10 analysts have issued 12 month target prices for Viking Therapeutics' stock. Their forecasts range from $12.00 to $27.00. On average, they anticipate Viking Therapeutics' share price to reach $16.44 in the next year. This suggests a possible upside of 141.1% from the stock's current price.
View analysts' price targets for Viking Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Viking Therapeutics' key competitors?

Some companies that are related to Viking Therapeutics include Shattuck Labs (STTK), PMV Pharmaceuticals (PMVP), Kura Oncology (KURA), NGM Biopharmaceuticals (NGM), Aurinia Pharmaceuticals (AUPH), Prestige Consumer Healthcare (PBH), Revance Therapeutics (RVNC), Myovant Sciences (MYOV), Viela Bio (VIE), Y-mAbs Therapeutics (YMAB), Kronos Bio (KRON), Zentalis Pharmaceuticals (ZNTL), Dicerna Pharmaceuticals (DRNA), uniQure (QURE) and Generation Bio (GBIO).
View all of VKTX's competitors.

What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the following people:
  • Dr. Brian Lian Ph.D., Pres, CEO & Director (Age 54, Pay $735k)
  • Mr. Gregory S. Zante, Sr. VP of Fin. (Age 49)
  • Mr. Michael Morneau, VP of Fin. & Admin. (Age 55)
  • Ms. Marianne Mancini, Sr. VP of Clinical Operations

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Pacer Advisors Inc. (0.01%). Company insiders that own Viking Therapeutics stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends for Viking Therapeutics.

Which institutional investors are buying Viking Therapeutics stock?

VKTX stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Viking Therapeutics or or view top insider-buying stocks.

How do I buy shares of Viking Therapeutics?

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $6.82.

How big of a company is Viking Therapeutics?

Viking Therapeutics has a market capitalization of $497.53 million. The biotechnology company earns $-25,780,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Viking Therapeutics employs 17 workers across the globe.

What is Viking Therapeutics' official website?

The official website for Viking Therapeutics is www.vikingtherapeutics.com.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.